BMC Urology (May 2023)

Immunohistochemical expression of the hepatocyte growth factor in chromophobe renal cell carcinoma

  • Maximilian Erlmeier,
  • Marie Mikuteit,
  • Stefanie Zschäbitz,
  • Michael Autenrieth,
  • Wilko Weichert,
  • Arndt Hartmann,
  • Sandra Steffens,
  • Franziska Erlmeier

DOI
https://doi.org/10.1186/s12894-023-01263-0
Journal volume & issue
Vol. 23, no. 1
pp. 1 – 6

Abstract

Read online

Abstract Background The prognostic value of Hepatocyte growth factor (HGF) in non-clear cell renal cell carcinoma (RCC) is still unclear. The aim of this study is to evaluate the prognostic impact of HGF expression in a large cohort of chromophobe RCC (chRCC). Methods Patients who underwent renal surgery due to chRCC were recruited. Clinical data was retrospectively evaluated. Tumor specimen were analyzed for HGF expression by immunohistochemistry. Results 81 chRCC patients were eligible for analysis, thereof 37 (45.7%) patients were positive for HGF. No significant associations were found for HGF expression and clinical attributes in patients with chRCC. Kaplan-Meier analysis revealed no differences in 5-year overall survival (OS) for patients with HGF− compared to HGF+ tumors (95.0% versus 90.9%; p = 0.410). Conclusions In chRCC HGF expression is not associated with parameters of aggressiveness or survival.

Keywords